

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Endurance RP Limited

壽康集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 575)

**LAUNCH OF MINDAGE[®] PSYCHOLOGICAL AGING CLOCK
KEY APPOINTMENTS TO SCIENTIFIC ADVISORY BOARD OF
DEEP LONGEVITY LIMITED
AND
POSSIBLE ISSUANCE OF SHARES UNDER GENERAL MANDATE**

The Company is pleased to announce that its wholly owned subsidiary, Deep Longevity, has today (after trading hours) launched its MindAge[®] psychological aging clock and executed two Consulting Agreements with recognised leaders in the fields of longevity biotechnology and longevity medicine, Dr Verdin and Dr Gladyshev in respect of the provision of scientific and business advisory services to Deep Longevity. Both Consultants will form an invaluable part of Deep Longevity's SAB and the Board looks forward to their expected contributions to the Group in conjunction with the development of Deep Longevity's business.

By way of consideration for their services under the Consulting Agreements for the entire term of services, unless otherwise agreed both Consultants will not receive any cash (save for expenses), but instead Dr Verdin and Dr Gladyshev will receive an award of 1,670,000 and 1,110,000 Consultant Shares, respectively, which shares will be subject to certain vesting conditions. The issue and allotment of the Consultant Shares is subject to there being sufficient capacity under the General Mandate and the Company's general mandate as at the relevant time in the future and therefore no shareholder approval is anticipated as being required in the year(s) of vesting under normal circumstances.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Shares.

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of Endurance RP Limited (the “**Company**” and collectively with its subsidiaries, the “**Group**”) is pleased to announce that its wholly owned subsidiary, Deep Longevity Limited (“**Deep Longevity**”) has today (after trading hours) launched its MindAge[®] psychological aging clock and executed two consulting agreements (the “**Consulting Agreements**”) with recognised leaders in the fields of longevity biotechnology and longevity medicine, Dr Eric Verdin, MD (“**Dr Verdin**”) and Dr Vadim N. Gladyshev, PhD (“**Dr Gladyshev**”, together with Dr Verdin, the “**Consultants**”, each a “**Consultant**”) in respect of the provision of scientific and business advisory services to Deep Longevity.

MindAge[®] Psychological aging clock

As previously disclosed in the Company’s announcement dated 2 September 2020, circular dated 18 November 2020 and the Company’s Annual Report 2020, Deep Longevity has been developing a broad range of biomarkers of aging to maintain physical health and wellness, restore youthfulness, and improve mental health and well-being. In this respect, the Company is pleased to report that Deep Longevity has today (after trading hours) announced the launch of its MindAge[®] psychological aging clock and the formation of a Science Advisory Board (“**SAB**”).

The MindAge[®] tests are now available via the Deep Longevity website <https://www.deeplongevity.com> and via the Young.AI iPhone App available in the Apple Appstore. It builds on the recently published paper titled “PsychoAge and SubjAge: Development of Deep Biomarkers of Psychological and Subjective Age Using Artificial Intelligence”.

The new survey-based MindAge[®] test is available at <https://www.young.ai/mind-age> and on the Young.AI iPhone App.

Reasons for the Consulting Agreements and issuance of the Consultant Shares

As previously disclosed in the Company’s announcement dated 2 September 2020, circular dated 18 November 2020 and the Company’s Annual Report 2020, upon acquiring Deep Longevity, Inc on 14 December 2020, the Group acquired its developing explainable and user-friendly artificial intelligence (AI) systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that

may slow down or reverse the aging processes. Deep Longevity's work in anti-aging and longevity medicine is motivated by better understanding and improving physical health and wellness, restoring youthfulness, and improving mental health and well-being.

Both Consultants are engaged as part of seeking to further understand the fields of anti-aging and longevity. Dr Verdin is the Chief Executive Officer ("**CEO**") of the Buck Institute for Research on Aging, while Dr Gladyshev is a professor at Harvard University, both in the United States ("**US**").

In this respect, both Consultants will join the SAB established by Deep Longevity and will provide Deep Longevity with scientific and business advisory services.

The SAB includes some of the most outstanding and credible researchers and medical doctors in the field working in the nascent field of longevity biotechnology and longevity medicine and is comprised of the following individuals:

- Dr Verdin, CEO of the Buck Institute for Research on Aging
- Daniel Kraft, MD, Stanford and Harvard trained physician-scientist and the founder of Exponential Medicine and Chair, Xprize Pandemic Alliance Task Force
- Morten Scheibye-Knudsen, MD, PhD, head of the biology of aging laboratory and professor at the University of Copenhagen
- Dr Gladyshev, professor at Harvard University
- Wei-Wu He, PhD, Chairman of Human Longevity, Inc

The SAB will be chaired by the Chief Longevity Officer of Deep Longevity, Alex Zhavoronkov, PhD ("**Dr Zhavoronkov**"), also the founder and CEO of Insilico Medicine IP Limited and adjunct professor at the Buck Institute for Research on Aging.

The SAB will help direct and review the Group's work in the development and applications of deep biomarkers of human aging. Given the extensive experience and highly credentialed qualifications of the Consultants, together with the other members of the SAB in these fields, their contributions as part of the SAB will be invaluable to the Group and such services are in line with past disclosures made and the Group's business scope.

Both Consultants will form an invaluable part of Deep Longevity's SAB and the Board looks forward to their expected contributions to the Group in conjunction with the development of Deep Longevity's business.

None of the other members of the SAB have been offered any Shares as compensation for their services on the SAB and, as such, no disclosure is required in this respect.

The Consulting Agreements contain customary terms and conditions in relation to term, termination, data protection, confidentiality and the protection of intellectual property and other property belonging to Deep Longevity.

The Chairman of Endurance RP Limited, and the founder of the London Longevity Week and The Longevity Forum, James Mellon, commented: "The scientific advisors of Deep Longevity are some of the highest-impact scientists, medical doctors, and most well-known experts in longevity. Under their leadership and supervision, Deep Longevity will continue developing and commercialising the biological and psychological aging clocks and engaging in research with the academic and medical institutions as well as with the insurance companies worldwide".

Dr Zhavoronkov commented: "Productive longevity is the most important asset we have in this life and Deep Longevity is dedicated to the measurement of aging at every level from biological to psychological. I am very happy to see Deep Longevity expanding into the psychology of aging as it impacts our physical and mental health and well-being and is one of the areas we can control and intervene in."

Possible issuance of Consultant Shares under general mandate as consideration for services

By way of consideration for their services under the Consulting Agreements for the entire term of services, unless otherwise agreed both Consultants will not receive any cash (save for expenses), but instead Dr Verdin and Dr Gladyshev will receive an award of 1,670,000 and 1,110,000 ordinary shares, respectively, with a nominal value of US\$0.01 each to be issued by the Company (the "**Consultant Shares**"), which shares will be subject to certain vesting conditions. Subject to the continuation of the Consultant's service for the Company pursuant to the relevant Consulting Agreement, one third (1/3) of the Consultant Shares will vest and become issuable on the first, second and third anniversaries of the award date,

being the date of the relevant Consulting Agreement. In the event that any of the Consultants' services cease and/or the relevant Consulting Agreement is terminated for whatever reason prior to the satisfaction of any vesting condition in respect of the Consultant Shares that may be issued to the Consultants, any unvested Consultant Shares previously awarded shall become null and void and any unvested Consultant Shares will not be issued or remain issuable to the Consultants and the Consultants will have no claim or entitlement in respect of such Consultant Shares whatsoever.

Following the satisfaction of the vesting conditions set out above, the Company will allot and issue the relevant Consulting Shares, and deliver the relevant Consulting Share certificates, to the Consultants within a reasonable period of time and thereafter the Consultants may sell their duly vested Consultant Shares as they see fit, subject at all times to the Company's internal policies and procedures in respect of share dealing.

Each of the Consultants has entered into the relevant Consulting Agreements in his individual capacity and will be the respective ultimate beneficial owner of the Consultant Shares, once issued. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, both Consultants are independent third parties and are not connected persons of the Group.

Price of the Consultant Shares

The number of Consultant Shares were determined using today's closing market price of HK\$0.166 per share of the Company (the "**Shares**") as quoted on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). This values the aggregate number of Consultant Shares at HK\$461,000 (or approximately US\$59,000), equivalent to an aggregate value of HK\$277,000 (or approximately US\$36,000) and HK\$184,000 (or approximately US\$24,000) to be received by Dr Verdin and Dr Gladyshev, respectively. Save in respect of any expenses and unless otherwise agreed, this is the only consideration the Consultants will receive for their services for the duration of their respective Consulting Agreements, assuming full vesting.

After adopting today's closing Share price, the price of the Consultant Shares represents:

- (i) a discount of approximately 1.19% to the closing price of HK\$0.168 per Share as quoted on the Stock Exchange on the last trading date preceding the date of the Consulting Agreements; and
- (ii) a discount of approximately 2.92% to the closing price of HK\$0.171 per Share as quoted on the Stock Exchange for the five consecutive trading days immediately prior to the date of the Consulting Agreements.

After adopting today's closing Share price and acknowledging the three-year vesting schedule of the Consultant Shares, the Consultant Shares represent an annual compensation to Dr Verdin and Dr Gladyshev of approximately HK\$92,000 (or approximately US\$12,000) and HK\$61,000 (or approximately US\$8,000), respectively, for each of the initial three years of service. This is benchmarked favourably against the average annual compensation for scientific advisors in the US, which ranges from US\$25,080 (or approximately HK\$196,000) to US\$160,000 (or approximately HK\$1,248,000) per year, with a median compensation of US\$45,300 (or approximately HK\$353,000). Moreover, the middle 60% of scientific advisors in the US make between US\$45,300 (or approximately HK\$353,000) and US\$80,000 (or approximately HK\$624,000) per annum, with the top 80% making US\$160,000 (or approximately HK\$1,248,000) per annum. On this basis the Directors are comfortable with the level of the compensation being offered to the Consultants, being the Consultant Shares.

For the reasons aforementioned, the Directors are of the opinion that the terms of the Consulting Agreements, including the quantum of the Consultant Shares for the services to be rendered, are fair and reasonable and that the Consulting Agreements and the Consultant Shares are in the interests of the Company and its Shareholders as a whole.

General mandate to issue the Consultant Shares

The Consultant Shares will be issued under and pursuant to the Company's existing relevant general mandate granted to the Board by the shareholders of the Company during the respective year(s) of vesting, and future general mandate(s) to be sought, and if thought fit, obtained. For the purpose of reference, the existing general mandate as approved at the annual general meeting on 28 May 2021 authorises the Board to allot, issue and deal with up to 479,884,243 Shares (the "**General Mandate**"). As at the date of this announcement, the Company had not utilised the General Mandate. The maximum number of 2,780,000 Consultant Shares to be issued pursuant to the Consulting Agreements represents approximately 0.58% of the General Mandate. The Consulting Agreements

expressly provide that any issue of Consultant Shares shall be subject to sufficient capacity under the Company's general mandate as at the relevant time in the future. The agreements further provide that in the event that the Company cannot or should not issue Consultant Shares due to applicable laws, regulatory requirements, constraints or otherwise, Deep Longevity and the Consultants will discuss in good faith what other forms of consideration are possible and practicable in the circumstances.

The 2,780,000 Consultant Shares represent approximately (i) 0.12% of all issued Shares as at the date of this announcement, and (ii) 0.12% of all issued Shares as enlarged by the issue of the Consultant Shares in full (assuming there is no other change in the issued share capital of the Company from the date of this announcement to the date of issuance of the Consultant Shares in full). Therefore, no shareholder approval is anticipated as being required in the year(s) of vesting under normal circumstances. Further announcement(s) will be made if and to the extent required if otherwise.

Ranking of the Consultant Shares

The Consultant Shares shall, when issued, rank in all respects *pari passu* with the existing Shares in issue, including the right to receive in full all dividends and other distributions declared, paid or made on or after their issuance. Save in respect of the vesting conditions referred to above, the Consultant Shares will be free from all liens, charges and encumbrances.

Application for listing

Application will be made to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the Consultant Shares on the Stock Exchange at or prior to their vesting.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Shares.

Note: Unless otherwise specified herein, the amounts dominated into US\$ have been translated, for the purpose of illustration only, into HK\$ using the exchange rate of US\$1.00 = HK\$7.80.

By Order of the Board
Endurance RP Limited
Jamie Gibson
Executive Director

Hong Kong, 14 July 2021

As at the date of this announcement, the Board comprises six Directors:

Executive Director:

Jamie Gibson (*Chief Executive Officer*)

Non-Executive Directors:

James Mellon (*Chairman*)

Jayne Sutcliffe

Independent Non-Executive Directors:

David Comba

Julie Oates

Mark Searle

* For identification purposes only